Verrica Pharmaceuticals, Inc. (VRCA)
4.11
-0.07
(-1.67%)
USD |
NASDAQ |
Oct 09, 16:00
4.10
-0.01
(-0.24%)
After-Hours: 20:00
Verrica Pharmaceuticals Net Income (Quarterly) : -13.15M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -13.15M |
| March 31, 2026 | -9.682M |
| December 31, 2025 | -8.074M |
| September 30, 2025 | -0.274M |
| June 30, 2025 | 0.204M |
| March 31, 2025 | -9.742M |
| December 31, 2024 | -16.20M |
| September 30, 2024 | -22.86M |
| June 30, 2024 | -17.19M |
| March 31, 2024 | -20.33M |
| December 31, 2023 | -24.61M |
| September 30, 2023 | -24.80M |
| June 30, 2023 | -10.99M |
| March 31, 2023 | -6.589M |
| December 31, 2022 | -5.932M |
| September 30, 2022 | 0.083M |
| June 30, 2022 | -10.17M |
| March 31, 2022 | -8.47M |
| December 31, 2021 | -9.54M |
| Date | Value |
|---|---|
| September 30, 2021 | -12.83M |
| June 30, 2021 | -11.78M |
| March 31, 2021 | -0.936M |
| December 31, 2020 | -12.98M |
| September 30, 2020 | -10.49M |
| June 30, 2020 | -9.409M |
| March 31, 2020 | -9.822M |
| December 31, 2019 | -7.637M |
| September 30, 2019 | -6.09M |
| June 30, 2019 | -7.001M |
| March 31, 2019 | -7.479M |
| December 31, 2018 | -7.578M |
| September 30, 2018 | -5.906M |
| June 30, 2018 | -5.317M |
| March 31, 2018 | -1.847M |
| December 31, 2017 | -1.435M |
| September 30, 2017 | -1.359M |
| June 30, 2017 | -1.095M |
| March 31, 2017 | -0.57M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
| Veru, Inc. | -6.988M |
| Johnson & Johnson | 5.534B |
| Eli Lilly & Co. | 7.095B |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 5.862M |
| Total Expenses (Quarterly) | 19.02M |
| EPS Diluted (Quarterly) | -0.6174 |
| Enterprise Value | 61.22M |
| Gross Profit Margin (Quarterly) | 85.02% |
| Profit Margin (Quarterly) | -224.4% |
| Earnings Yield | -40.70% |
| Normalized Earnings Yield | -39.68 |